Wellcome Leap Inc.

Wellcome Leap is not a conventional foundation and should not be approached as one. Founded in 2020 by the Wellcome Trust, it operates explicitly as a 'global ARPA for health' — a reference to DARPA, the U.S. defense research agency that funded the internet, GPS, and stealth technology. CEO Regina Dugan is a former DARPA Director and Google ATAP lead; COO Kaigham Gabriel is a former DARPA program manager. This lineage is not incidental: it defines every dimension of how Leap funds research.

Rather than issuing open calls for any health research, Wellcome Leap defines specific, bold programs with quantified outcome targets — 'reduce stillbirth by 50%,' 'double depression treatment effectiveness,' 'reduce heavy menstrual bleeding diagnosis from 5 years to 5 months.' Each program is structured around 'thrust areas,' which are defined technical approaches or sub-problems that Leap has decided are most promising. Applicants do not propose their own research agenda; they propose how they will contribute to achieving Leap's pre-defined breakthrough.

This means the single most important step for any prospective applicant is program fit. Before writing a single word of your abstract, study the current open programs and their thrust area descriptions in detail. Ask yourself not 'does our work relate to women's health?' but 'can our specific capability move the needle on Thrust 2 of VISIBLE's microvascular diagnostic challenge?' If the answer is no, do not apply to that program.

Eligibility is genuinely global and unusually inclusive. Universities, research hospitals, companies (including venture-backed startups), non-profits, and even regulatory or professional bodies can all apply — from any country. No prior relationship with Wellcome Leap or its Health Breakthrough Network is required, though joining the Network (via executing a MARFA or CORFA agreement) is required before any award is executed.

First-time applicants should also understand that Leap deliberately avoids large consortiums at the application stage. Applying as an individual investigator or small team is encouraged; Leap facilitates partnerships between performers after selection. Come in lean and expert, not broad and collaborative.

Wellcome Leap's financial profile reflects a capital-intensive, program-driven funding model unlike almost any other foundation in health philanthropy. The organization was capitalized with approximately $307 million from Wellcome Trust in 2019, received an additional $333 million infusion in 2021 (bringing total assets to $553 million at peak), and has since announced at least one more $335 million tranche from Wellcome Trust. The $100 million Pivotal Ventures co-investment announced in September 2025 adds further runway. Total capital received exceeds $1 billion.

The IRS 990 data shows total giving of $158.6 million for the most recent available period (fiscal years 2022-2023), up from $87.2 million in 2021 and $14.4 million in 2020. Current assets per the foundation record stand at $252 million, reflecting active deployment of capital into programs. The gap between assets received and assets held confirms this is a high-velocity deployer: they spend, not hoard.

Individual program budgets run $45-60 million each, committed over 5-7 year timelines across multiple performers. Programs confirmed with their total budgets: Dynamic Resilience ($60M), VISIBLE ($55M, jointly with Pivotal), Delta Tissue ($55M), CARE ($50M), Untangling Addiction ($50M), Q4Bio ($50M), SAVE ($50M), In Utero ($50M), MCPsych ($50M), HOPE ($50M), The Missed Vital Sign ($50M), and 1kD ($45M).

Individual performer award sizes are not disclosed publicly, but since each program funds multiple performers across multiple years, individual contracts likely range from low hundreds of thousands to several million dollars, with exceptional performers potentially receiving larger follow-on tranches. The 990 data shows 'grants paid' of only $480,753 in 2022, which likely reflects accounting classification — Leap funds performers through program agreements (MARFA/CORFA contracts) that may be classified as program service expenditures rather than traditional grants. Full direct and government-certified indirect costs are allowable, which is significant for academic researchers who need to recover overhead.

Geographically, the 14 active programs span 30 countries with 160+ participating institutions. The United States is the administrative home, but funding flows globally with no geographic preference among performers.

Wellcome Leap occupies a distinctive position among health-focused foundations — it is simultaneously larger in capital base than most peers, more concentrated in focus, and structurally incomparable in methodology. The following peers share an NTEE Health classification and broadly similar asset ranges, but none operates on the ARPA program model.

Peer giving estimates are approximate, based on 5% standard payout; actual figures vary. What the table obscures is the structural difference: Wellcome Leap deploys 10-20x more capital per year than most peers of similar asset size because it is actively spending down while receiving ongoing infusions from Wellcome Trust. A researcher who qualifies for Glenn or Hillblom funding can apply there independently; Wellcome Leap performers must align to predefined program goals. For organizations with that alignment, the scale of potential engagement is unmatched in private health philanthropy.

The twelve months between September 2025 and March 2026 represent one of Wellcome Leap's most active public periods since launch.

In September 2025, Leap and Pivotal Ventures (the philanthropic investment fund of Melinda French Gates) announced a $100 million co-investment in women's health, explicitly framing it as a step toward a $1 billion philanthropic goal for this disease area. The announcement cited the statistic that women spend an average of nine more years in poor health than men, and that only 1% of global health research funding in 2020 addressed women's health beyond cancer. Two new programs were announced for 2026 launch under this partnership.

In February 2026, the first of those two programs launched: VISIBLE, a $55 million global research initiative targeting ischemia with non-obstructive coronary arteries (INOCA) and related microvascular conditions that disproportionately affect women and are frequently misdiagnosed or dismissed. The British Heart Foundation publicized performer recruitment alongside the launch.

Wellcome Trust's additional $335 million commitment — announced as part of Wellcome's pledge to allocate ~5% of future funding to Leap — reinforced the organization's financial continuity. Existing programs meanwhile have produced measurable results: a maternal blood test for fetal growth restriction has demonstrated greater than 80% predictive accuracy (In Utero program); Alzheimer's endocrinology work is targeting a 50% reduction in lifetime risk (CARE program); and the Foundations of a Resilient Microbiome program has selected its first performers, including researchers from Cambridge and Northeastern University.

The most common mistake grant seekers make with Wellcome Leap is approaching it as a responsive funder. Leap does not accept proposals on topics applicants choose; it funds performers who can contribute to specific outcomes on programs Leap has already designed. Every application must map explicitly to a program's thrust areas — not just the program's general subject matter.

Timing: Programs open calls on a rolling basis as new initiatives launch. The best time to engage is immediately after a new program is announced, before the first abstract deadline. Monitor wellcomeleap.org and the organization's LinkedIn page for launch announcements. Once a program's first abstract cycle closes, the window for joining as a new performer may not reopen.

Abstract strategy: Leap's abstract review is a genuine filter. Reviewers are looking for specific technical capability that addresses a defined thrust, quantified outcome projections, and evidence that your team can actually execute. Avoid aspirational framing ('we will explore,' 'this may lead to'). Use the language of the thrust area description verbatim where appropriate — this signals you have read and understood the problem definition.

Who submits: The Principal Investigator must submit via the online portal. Co-PIs are allowed without limit and should be listed, but the PI's institution will be the contracting party. Ensure your PI's institution can execute a MARFA agreement (for academic/nonprofit entities) or a CORFA agreement (for commercial entities) before submission — delays in agreement execution can delay award even after selection.

Questions and relationships: Email the program-specific team early (e.g., care@wellcomeleap.org, visible@wellcomeleap.org). Program directors are scientists who engage substantively with pre-application questions. A brief, well-framed question can yield clarification that improves your abstract significantly — and program staff remember applicants who demonstrated genuine understanding.

Multiple submissions: Applicants may submit to more than one thrust area within a program, and to more than one program simultaneously. If your work genuinely spans thrusts, submit separately to each rather than trying to cover both in a single abstract.

Network membership: Joining Wellcome Leap's Health Breakthrough Network by executing a MARFA or CORFA is not required to apply, but is required to receive an award. Begin the agreement process the moment you submit — institutional legal review can take weeks.